Medicines
Boldly reshaping the future of cancer care
We are developing novel oncolytic immunotherapies designed to address a broad range of cancer indications.
TUDRIQEV (vusolimogene oderparepvec)
Bringing new hope to patients with advanced melanoma
Patient Support
ReplimuneConnect Plus can help patients start and stay on treatment with dedicated support and resources focused on patient care.